X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS
GE HealthCare Technologies Inc. Common Stock
GEHC
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Last trade$82.56
Day change-$0.40 (-0.48%)
Day range$82.12 – $83.62
Volume1,244,260
Market cap$37.51B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$37.51B
Price / earnings
17.41×
Price / book
3.23×
Price / sales
1.73×
EV / sales
2.06×
EV / EBITDA
11.76×
Profitability
Earnings per share
$4.76
Return on assets
5.61%
Return on equity
18.55%
Dividend yield
0.17%
Liquidity and leverage
Debt / equity
0.86×
Current ratio
1.3×
Quick ratio
1.01×
Cash ratio
0.32×
Cash flow
Price / cash flow
15.54×
Price / free cash flow
19.87×
Free cash flow
$1.89B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GEHC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$5.51B
$5.3B
$5.13B
$5.7B
$5.14B
$5.01B
$4.78B
$5.32B
Cost of revenue
$3.29B
$3.12B
$3.15B
$3.44B
$3.15B
$3.02B
$2.77B
$3.04B
Gross profit
$2.22B
$2.18B
$1.98B
$2.26B
$1.99B
$1.99B
$2.01B
$2.28B
Selling, general and administrative
$1.1B
$1.12B
$1.12B
$1.11B
$1.05B
$1.03B
$1.04B
$1.13B
Research and development
$320M
$323M
$345M
$323M
$292M
$302M
$344M
$344M
Total operating expenses
$1.42B
$1.44B
$1.46B
$1.15B
$1.34B
$1.33B
$1.38B
$1.07B
Operating income
$805M
$739M
$515M
$1.11B
$653M
$654M
$629M
$1.21B
Interest expense
-$122M
-$114M
-$96M
-$105M
-$111M
-$113M
-$110M
-$121M
Income before taxes
$752M
$693M
$505M
$821M
$643M
$613M
$692M
$834M
Income taxes
$129M
$119M
$94M
$219M
$179M
$113M
$104M
$96M
Net income
$623M
$574M
$411M
$602M
$464M
$500M
$588M
$738M
Net income attributable to common shareholders
$615M
$561M
$389M
$589M
$446M
$486M
$564M
$721M
EBITDA
$968M
$899M
$668M
$1.26B
$801M
$802M
$765M
$1.35B
Basic earnings per share
$1.36
$1.24
$0.85
$1.30
$0.98
$1.06
$1.23
$1.59
Diluted earnings per share
$1.36
$1.24
$0.85
$1.29
$0.98
$1.06
$1.23
$1.57
Recent news
Company coverage with links to the original publishers.
GE HealthCare Technologies (GEHC) is well-positioned for growth with a record $23.7 billion backlog (up 12%), strong Pharmaceutical Diagnostics revenue growth, and raised 2026 guidance. However, persistent component inflation, tariff uncertainty, and China's fragile recovery pose risks to margin expansion.
In a comparison of two Medical-Products sector stocks, GE HealthCare Technologies (GEHC) emerges as the better value option compared to Stryker (SYK). GEHC has a Zacks Rank of #2 (Buy) with stronger earnings estimate revisions, a lower forward P/E ratio of 16.53 versus SYK's 20.86, and a superior Value grade of B compared to SYK's D grade. GEHC also shows better valuation metrics across PEG and P/B ratios.
GE HealthCare Technologies announced the formation of the MAGNUS Neuro Alliance, a collaborative research network using its head-only 3.0T MR system to advance neuroscience research. The alliance will unite leading institutions for multi-site trials and research focused on developing MRI-based biomarkers for neurological diseases. GEHC stock declined 2.2% following the announcement, though the initiative could strengthen the company's position in advanced imaging and create long-term growth opportunities.
GE HealthCare raised its full-year 2026 organic revenue guidance to 4% and reported 6.2% organic revenue growth in Q3 2026. The company's equipment backlog grew 12% year-over-year to $23.7 billion. Key strengths include recurring revenue from its Pharmaceutical Diagnostics division, operational improvements through the Heartbeat operating system, and multiyear supply agreements for memory chips that provide manufacturing resilience amid industry shortages.
Alcon Inc. (ALC) reported Q3 2026 core EPS of 91 cents, beating estimates by 2.3%, but net sales of $2.72 billion missed consensus by 0.6%. While Vision Care and Equipment segments showed strength, Implantables sales declined 2% due to competitive pressures. The company narrowed its 2026 guidance, expecting 6% constant-currency net sales growth and 12-14% core EPS growth, which weighed on investor sentiment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Oct 23, 2026
$0.04
Nov 13, 2026
recurring
Jul 24, 2026
$0.035
Aug 14, 2026
recurring
Apr 2, 2026
$0.035
May 15, 2026
recurring
Jan 9, 2026
$0.035
Feb 13, 2026
recurring
Oct 24, 2025
$0.035
Nov 14, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.